参考资料:[1] Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer. Retrieved April 11, 2024 from https://ir.arvinas.com/news-releases/news-release-details/arvinas-enters-transaction-novartis-including-global-license
[2] 2024 AACR重磅摘要|海创药业6项全球首创肿瘤药物研究成果亮相发布!Retrieved April 11, 2024 from https://mp.weixin.qq.com/s/-Z8IgtMBHSYonfcTCfNbpA
[3] 华东医药HPK1 PROTAC研究项目HDM2006即将亮相AACR 2024. Retrieved Mar 25, 2024 from https://mp.weixin.qq.com/s/5Dy3VecYjYEqceh_JCOkaQ